Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS
Home/The Filing Wire/Tvardi Therapeutics, Inc./ 10-Q

Quarterly Report · 10-Q

Tvardi Therapeutics, Inc.

TVRDNASDAQEQUITYCurrent

Quarterly Report

Filed Aug 14, 2026Accepted Aug 14, 2026, 7:10 AM EDTCIK 1346830Accession 0001104659-26-096424
View company →Permanent SEC source ↗
Share

Company context

Tvardi is a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases with significant unmet need. STAT3 is a central mediator across critical signaling pathways that drive uncontrolled proliferation, survival and immune dysregulation. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. The Company is conducting clinical trials with TTI-109 in healthy volunteers and TTI-101 in hepatocellular carcinoma (NCT05440708). To learn more, please visit tvarditherapeutics.com or follow us on LinkedIn and X (Twitter).

Current securities

TVRDNASDAQ · EQUITY · Current

Recent company filings

  1. Results of Operations and Financial ConditionAug 14, 2026
  2. Regulation FD DisclosureJul 30, 2026
  3. Other EventsJul 17, 2026
  4. 424B5 filingJul 17, 2026
  5. Regulation FD DisclosureJul 7, 2026

Registered securities in this filing

TVARDI THERAPEUTICS, INC. · 10-Q · Filed 2026-08-14

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, par value $0.001 per share

Symbol
TVRD
Exchange
NASDAQ
Classification
COMMON
Status
Current
Filing context

Context: Duration_1_1_2026_To_6_30_2026_HsKcXHA9YEOjRiSPKflkQQ

Dimensions: Not supplied

Accession 000110465926096424 · 1 registered-security cover member

Read the exact SEC filing ↗

As-filed source

Primary evidence
As filedOpen full document ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.